ArticleJournal of orthopaedic surgery and research2025
miR-340-5p alleviates the damage effect of LPS on nucleus pulposus cells by negatively regulating the expression of SOX4.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- miR-4632-5p Alleviates Lumbar Disc Degeneration by Targeting MAP3K11: A Novel Role in Mitigating Nucleus Pulposus Cell Degeneration.Biochemical genetics · 2026Article
- MiR-766-3P promotes degenerative lumbar disc disease by regulating SIRT6 to aggravate the inflammatory response of human nucleus pulposus cells.Hereditas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies show that about 80% of lumbar disc degeneration (LDD) patients experience back or leg pain, affecting their quality of life. However, the causes of LDD are not fully understood. This study focused on exploring the expression level of miR-340-5p and SRY-related high-mobility-group box 4 (SOX4) in LDD and attempts to clarify its potential mechanism in the pathological process of LDD.
methodsA total of 88 patients with LDD and 80 non-LDD patients were continuously included in this study. The miR-340-5p levels in nucleus pulposus (NP) tissues were measured using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). The potential diagnostic significance of miR-340-5p for LDD was evaluated by generating a Receiver Operating Characteristic (ROC) curve. The impacts of miR-340-5p on Lipopolysaccharide (LPS)-stimulated NP cells were analyzed through the Cell Counting Kit-8 (CCK-8) method, and apoptosis levels were quantified using flow cytometry. Additionally, the concentrations of inflammatory cytokines and extracellular matrix (ECM) remodeling markers were assessed with Enzyme-Linked Immunosorbent Assay (ELISA) kits.
resultsmiR-340-5p was abnormally down-regulated in LDD patients and the ROC curve showed that miR-340-5p has diagnostic value for LDD (AUC = 0.909, sensitivity = 81.8%, specificity = 85.0%, cutoff value = 0.815). Additionally, the enforced expression of miR-340-5p promoted proliferation and ECM remodeling and inhibited the level of apoptosis and pro-inflammatory factors in LPS-damaged NP cells. However, overexpression of SOX4 counteracted the effects of miR-340-5p overexpression on LPS-induced NP cells.
conclusionsmiR-340-5p alleviates the damage effect of LPS on NP cells by negatively regulating the SOX4, and miR-340-5p may be a potential therapeutic target for LDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.